our the would XX, welcome everyone ended call Thank you March like to Susan. for I XXXX. quarter to
for Research American to submissions. or half upcoming for Cancer have various Meeting, the of CG-XXX, news and option ago Although initiatives, a from initiation our to and publications, includes This of exercise update milestones, just much our Association capture we clinical the timelines the fully report. call recent a trials AACR month for Annual anticipated was last license R&D
know As that remind about positive unexpected affect projections. expectations will also you but or I'm negative events our you candid can either my
CFO, and we review Chow updates will for will open call Mr. then Greg your quarterly financials our the our these Following questions.
So start to early CrystalGenomics license announcement most with of option it. our as to let's from XXX I’ll recent or exercise based regarding refer CG-XXX our Korea the
Our an certain with pan-FLTX of and kinase for patients and oral the developed as AML BTK malignancies. inhibitor treatment being agent B-cell
no the challenges. attendant so a not an potential formal a AML Japan, into to the and Xth the agreement. of and allowed gained competitor XXXX on We And these very XXX As its in XXX endeavors of and no of estate June this][ph] exercise absence the its advancements the before early Monday agreement we to to full May solved the a of molecule was We [sense a executed but option there early anti-tumor we've initial of in cancer of Since ourselves in capacity the the progress route of IP molecule agreement and we IP efficacy that us and week. superior Because B-cell the of allowances relative that U.S. announced to full we and with in data, and talks molecule confidence better for manufacturing, and and license in toxicity. XXX to to we kill qualities invested CrystalGenomics drugs. patent of this its chemical to option mentioned even synthetic received mechanistic its the had for activities was obtain understanding scale We vet as committing made up was saw obligations as We've that and the the stage entered EU, previously in time or appreciation were the an in viewed that the definitive. unveiled IP estate. decision there option license gained was and notices Australia. cells allowed
exercise With regulatory will global $X option, all payment a commercial honored were royalty licensed make licensed rights territory. based Aptose and the in that China, outside and XXX indications to commercialize territory. of now of and develop exercising we CrystalGenomics to on million payment. also CrystalGenomics owns and receive for payments the the milestone and Korea a to The triggered sales
AACR disclosed for at for I poster B-cell XXX Now XXX data but partners application then At and held our had research our malignancies. let's mid Chicago AML CG-XXX and presentations; Aptose will Meeting. on was XXXX APTO-XXX two on with regarding now separately AACR discuss focus one which its to data and in on April three
referred approximately driver mutation reminder the a a as of the of bone a is disease the receptor kinase devastating and tyrosine As of in AML have heterogeneous is and these and patients a mutation ITD key FLTX the marrow and in the ITD to third FLTX blood cancer patients.
discoveries With development FLTX of the first the generation inhibitors. came these scientific
by in unmedical but year the became cells. other transient as develop of kinase development the AML. driven can still drug benefit of additional can pathways for midostaurin that Midostaurin FLTX because AML last need inhibitors and great remains provide mutations first various can Just and actions approved patients can non-ITD Thus a kinase inhibitor. in resistance benefit be rescue
kinase, relevant of as the including insufficient PDGFR Aurora disease AKT, emerge BTK, that other to those from Our also and even meaning include in to compartment resistant Moreover associated forms cancers AML if of and picomolar and inhibitors other inhibitor poor with CSF-XR inhibitors. arise pathways mutant alpha. compound patients because the all only AML In rendered FLTX which AURK, derived low known against the that that the the other to retains bone pan-FLTX are known is pathways it all FLTX of prognosis nanomolar kinase driven potency FLTX XXX for is rescue cells. to AML forms clinically rescue AML, marrow forms FLTX, control FMS, FLTX
a cluster, presentations which related kinase BXXXX] my XXX are The tolerability inhibition that include has includes which kinase that that the inhibition CSFXR, but safety other product T.E.C., inhibit by with from that the You'll potently includes and in inhibit four, kinase does the AML XXX the multi clusters downstream these the pathways clusters the in one, PDGFR concerns inhibitor kinases. the and BTK pathways kinases inhibitors. track of for BLK, BTK, TEC, results been cluster inhibited kinase are deemed cluster; not cluster families and FLTX recall and not cancers. ITK; XXX or and other certain cluster responsible and three, two, alpha; of AKT ERK But B-cell Aurora of [ph] certain EGFR, [ERK operative kinase FLTX,
become and As cyto AML a in high about AML of development risk effective of deal of that may the toxic a at potent that patients older therapy apparent great and agents. of and XXX AACR. at subset patients cannot our inhibitor ITD, presentations an of the There's excitement FLTX superior and was any tolerate XXX
Brian XXX research the of Kurtz, poster from Dr. as the Science and AACR first with including Dr. University team patients Dr. Druker's malignancies. beat demonstrated Health part was marrow AML From Brian bone This Druker, specimens Our Steve Tyner. research broad Oregon hematologic against Cancer activity nice of or the primary by various initiative. Jeffrey conducted Institute OHSU the and entire at at
As animal performed XXX. that you're a multiple of demonstrate have anti-cancer aware we studies efficacy strong
malignant laboratory of are in cells However, such in not fully grown representative the xenograph studies and cells use AML patients.
XXX AML FLTX taken directly against broader from before elicits studies mutated So team FLTX and performed sorafenib, and that take freshly of wanted kinase demonstrated inhibitors including XXX we if these samples true AML the was cancer FLTX from relative cases. quizartinib, FLTX-ITD XXX bone bone gilteritinib, marrow the other with marrow greater crenolanib, patients patients collected sensitive especially samples clinic XXX are and midostaurin, domain This of relative AML to tyrosine positive we set dovitinib. a other at in potency to to to to Dr. Druker's OHSU cells inhibitors. ask
also all FLTX of and samples. a and expression I the clinical B-cell certain or trials Separate activity the to the range the XXX pathways to rescue large are multiple cell many patients. as MCL, enhanced in site from B-cell irreversible Indeed chronic signaling, or due CLL, wild scatter in of beneficial forms and that BTK Although potency data and plots These of reveal malignancy others. patients. activities FLTX of described FLTX can the its target suppress to earlier. BTK the observed was type drive superior mantle AML covalent provided of and in be striking heat these as of maps story, such molecule which lymphocytic advancement for AML AML oncogenic patients were lymphoma XXX in enzyme or and such ibrutinib as justified inhibitors can leukemia active BTK Therapy lymphoma existing over residue diffused of DLBCL, the with ability
well However therapy. by disease treatment and discontinuation can by to other as lead ibrutinib with as can inhibitors resistance challenges and be acquired refractory BTK intolerance limited which of
our cells, and indirectly of XXX billion for approved XXX potently through to CLL cells in average cells. involves and at BTK the against CLL presented with AML pathways covalent study than have These were was suppress distinction unaffected CLL CLL inhibition XXX XXX the reported also to Furthermore to also the The other for the to potency a B-cell inhibitor be on XXX potency ability malignancies. are times CLL as Again AACR, of remind approximately billion treatment viewed other demonstrated derived of in-vitro and that lines ibrutinib stromal of inhibitors ibrutinib. against in and cells. XXX rescue the driven directly and superior patient and mechanism ex-vivo stromal But multiple ibrutinib. cell of care kills are to that And FDA Thus superior of To kills data XXXX against cell isolated BTK cells primarily those a also those patient CLL kinase XXX sensitive of cells B-cell we its inhibitor, is the of CLL head inhibits Ibrutinib ibrutinib its direct the XXX shown that findings than viability. act to another from indirect loss due for FLTX malignancies. As bone samples migration greater marrow malignancy the the an activity supporting of multiple marrow the appears BTK promote To CLL killing cell studies and samples to malignancies XXX cells B-cell between range to compared signaling suppress from a more done more that and and continues in potency CLL operative head of range to the the studies cells standard inhibitors BTK and drug. vast ability signaling other ask and to retained cells operative you by BTK patients B-cell on of B-cell just $X and bone to contrast ibrutinib. in wealth BTK derived major year other the OHSU and significantly will be ibrutinib majority that team we of CLL were if must due $X like CLL ibrutinib. affect pathways. XXX then summarize and current than is grow. to development AML and freshly conditions demonstrate
Now let's and XXX that to in induced this discuss quizartinib Aptose those second of through apoptosis FLTX-ITD which cells was inhibition demonstrated research poster AML in signaling our positive XXX superior cells pre-clinical study. in the FLTX team
most and gatekeeper tested was cells patients and XXX tyrosine wall malignant potently of a in third patients, decreased tested found quizartinib, signaling. the or AML gilteritinib malignancies FLTX superior not exclusive and ibrutinib found B-cell type XXXX B-cell cell inhibited be against of that the colony phosphorylation an in inhibitors be one AML with XXX BTK innovation all more domain type have lines and non-ITD and could approximately times FLTX mutations Although in fraction B-cell kinase in express BTK FLTX mutations. to to inhibited is lines In AML to proliferation formation AML effect explained by XX which housing of crenolanib than wall FLTX-ITD patients and lesser were -- FLTX the cells domain. the
like BTK the also stromal inhibits to As cells. a cells on has cells. to nurse just is the indicated moment of ibrutinib indirect in inhibitors. bone thereby potently to considered emphasized is that it reported it lead ago pathways lead does BTK act of the to other ibrutinib to XXX can direct CLL BTK in been cells I promote not ibrutinib direct apoptotic BTK But cells CLL the from death the additional of XXX Like inhibit and the but primarily indirect CLL of Rather killing that typically killing to ibrutinib marrow those the CLL killing lead cells. XXX and and targets differentiating
So type signaling malignancies BTK up with of we the FLTX understanding aberrations. XXX. AACR XXX potent and genomic wall continue ability to And producing pathways wrap all the our of inhibit of XXX, of to advance of killing direct and target to data different types scientific multiple to mutant forms and key diverse driven by demonstrated
potentially drugs. through cells XXX were at mention quickly with data to other of here accepted kinase presentation demonstrated inhibitors and ability that abstract recently an resistance in time. XXX cluster in is to potency Stockholm the European multi look has kill we other to that EHA ability oncogenic sharing notified pan-FLTX/pan-BTK of As multiple and just more that the had at for Association also June broad animal in pathways greater would tolerated to of models or meeting to been a relative inhibitor forward like inhibition range that on we overcome to I Hematology well
studies clinical of for We that. us have are of and prepare these pursue development all to indeed eager XXX helped
So CG-XXX. are the where in development of we
early GLP high chemistry selected studies crafted studies readily for to wedding and allows material co-milled kilogram we we agent. markerized to XXX of quantities manufacture be [ph] us First, multi human a synthetic toxicology formulation with a a that pathway the with purity,
second and this GLP have you completed kilos during GLP IND of of so to this And efficacy range product multiple dose studies We dogs. year. drug quarter finding quarter we're the in enabling again completed studies animal multiple To dogs, imminently. and substance halfway those for studies plan studies rodents remind toxicology toxicology GLP and studies, prepared second in drugs of the we planned year begin through are rodents
our then with We're plan Designation addition the IND human data indications a most we X initiate XXX for malignancies. B-cell trial second AML that track studies that timelines and emerged To in those includes to submit initiate soon as year to into Drug the patients support still thereafter. and Orphan with colleagues to received first patients remind the includes keep are you eager to designation to drive we AML on clinic we other patients plan a Phase In for trial various and XXX seek such year you as to Me the in progresses. and this will abreast of and expect we indications.
of broad may c-Myc in has and is in expression. have turn suggests now notoriously Because cell and XXX well c-Myc research Aptose's is oncogene a many regulates that end malignancies indications. oncogene inhibit growth to to certain expression. c-Myc AML a c-Myc tumor including our small application So malignancies cancer solid cancers many molecule expressed apoptosis over target inhibitor let's been difficult key APTO-XXX. across hema and cancers other in The as as it
of presented just AACR. at research a in Some that recently was poster
found damage XXX structures the are with replication force found poster quadruplex response suppress Myc trigger mechanism the in team we cells. and One in can leading and of action quadruplex certain quadruplexes programmed XXX. of Myc stabilizing of XXX XXX structure to death. BRCAX that such region BRCAX cancer those that mutated found Such heightened stabilizing Myc induction the multi promoter can DNA of certain is cancer and gene of and in cell For [indiscernible] the the demonstrated DNA research stabilizes depletion sensitivity cells of or sensitivity of The to structures. that explored cells transcription the gene in also
impaired cells far damage XXX. were mutations DNA can As functions. functions we DNA to and to as BRCAX or Indeed lead cells have the BRCAX and a a DNA cancer response found in synthetic repair drug by situation repair faulty with highly lethal studies sensitive that that
approved Myc mutation BRCAX exhibit solid hereditary acts findings with partnering to particular comparable can exhibit leverage publication Aptose now Therapeutics These recently an causes by that and in XXX cells lethality with ovarian, we prostate tumor olaparib. must in to on AML. two for for against wish and in BRCAX mechanisms online potential DNA of by lethality deficiencies. leads cancer people or XXX mention acts that and to which articles different of breast, I cancers to they that focus maintain the action a journal, we JAK The development via the Although some synthetic including that inhibitor we synthetic for new but repair cancers. XXX XXX AML and also reveal provide XXX. opportunities these Cancer inhibition must Molecular that we mechanism a indications of details AACR patients sensitivity findings cells with in mechanism remember published Hopefully FDA
our understanding made XXX to addition significant scientific we've In of development. progress -- with progress advancements XXX and
will that the for then batches the You multiple substance have manufactured drug prototype a placed on optimized CMC successfully optimized hold manufacturing, was formulation, and product we of related drug drug solubility matter. XXX clinical Since recall the process, manufacturing engineering optimized product. have and
well few AML. have we now has on questions a a this XB response and secured and response studies FDA Remember we soon plan more those accepts the we If sites and syndromes, new clinical approvals the passed from and the they stability, XXX or sterility, clinical minor supply trial of hope second of These have drug during trial and this to been studies lifted either through trial. hear lifted AML our track both phases in of submit RFB clinical the the Orphan thereafter. completed patients have or FDA immediately. quarter. participate that back fusion we been in patients Drug manufactured fitness the dosing are and tests XXX for order complete required to during a Designation dozen with of in has hold FDA clinical this of expansion drug product first demonstrate or performing During and as to with patients successfully clinical do MDS. screening more and we we product to animal have pushed GMP studies a A of as the in CMC bridging the quarter quarter then year usage. and Xb open reinitiate based escalation And if Phase have no Phase expect sites these the an is couple to XXX then begin dose for myelodysplastic hold to to early the AML With findings
So XXX patients. we're restarting eager the hopeful inhibitor the and are soon physicians of of treatment a trial for test the AML Myc clinical to
Aptose public to we insight analyst add private know another We years very and for Ms a pleased So to to Morgan the at seven. bring order Loewy's forward you number her and turn dimension financials in our both our and the Board Chow last industry. look recently of our Loewy leader keen biotechnology to business Board of Board Aptose is we know past positions that our much Members biotechnology Mr. Ms. over and an will executive working from Many companies Caroline Prudential. senior brings CFO her. to respected of with I'm and Stanley and I Ms. Directors. very accomplished before it of her for appointment as at her welcome that Caroline Loewy
milestones So more month important half and it's XXXX. to forward look a been a and we during busy
Greg. review will Officer, will Greg turn the I certainly keep now We to Financial Chief you the our results over call Mr. our for quarter. will who Chow posted.
